Zhejiang Tailin BioEngineering Co.,Ltd

Equities

300813

CNE100003S89

Advanced Medical Equipment & Technology

End-of-day quote Shenzhen S.E. 03:30:00 28/05/2024 am IST 5-day change 1st Jan Change
20.47 CNY +0.49% Intraday chart for Zhejiang Tailin BioEngineering Co.,Ltd -3.40% -16.52%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Zhejiang Tailin Bioengineering Co.,Ltd Announces Final Dividend Implementation Per A Shares for the Year 2023, Payable on 27 May 2024 CI
Zhejiang Tailin BioEngineering Co.,Ltd Proposes Final Cash Dividend for 2023 CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Tailin Medical Engineering Co., Ltd. announced that it expects to receive CNY 170 million in funding from Zhejiang Tailin BioEngineering Co.,Ltd CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Tailin Bioengineering Co.,Ltd Approves Cash Dividend for the Year 2022, Payable on 11 May 2023 CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Tailin Bioengineering Co.,Ltd. Proposes Final Cash Dividend for 2022 CI
Certain A Shares of Zhejiang Tailin BioEngineering Co.,Ltd are subject to a Lock-Up Agreement Ending on 15-JAN-2023. CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Tailin Medical Engineering Co., Ltd. announced that it has received CNY 40 million in funding from Zhejiang Tailin BioEngineering Co.,Ltd CI
Zhejiang Tailin Bioengineering Co.,Ltd Approves the Final Cash Dividend for the Year 2021, Payable on May 18, 2022 CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Tailin BioEngineering Co.,Ltd Proposes Final Cash Dividend for the Year of 2021 CI
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Tailin Life Science Co., Ltd. announced that it expects to receive CNY 40 million in funding from Zhejiang Tailin BioEngineering Co.,Ltd CI
Zhejiang Tailin Bioengineering Sells $33 Million RMB Convertible Bonds MT
Zhejiang Tailin BioEngineering Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zhejiang Tailin Bioengineering Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Zhejiang Tailin Bioengineering Co.,Ltd Approves Cash Dividend for the Year 2020, Payable on May 26 , 2021 CI
Zhejiang Tailin BioEngineering Co.,Ltd Proposes Final Dividend for 2020 CI
Zhejiang Tailin Bioengineering Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Zhejiang Tailin Bioengineering Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Chart Zhejiang Tailin BioEngineering Co.,Ltd
More charts
Zhejiang Tailin Bioengineering Co., Ltd. is a China-based company mainly engaged in pharmaceutical equipment business. The Company's main business is the research, development, manufacturing and sales of microbial detection and control technology system products, organic substance analysis instruments and other pharmaceutical equipment. Specific products include various consumables, instruments and equipment, which can be used alone or in combination for the production and quality of sterile drugs. The application areas that can be expanded include medical and health, food safety, disease prevention and control, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection. The Company distributes its products within domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 300813 Stock
  4. News Zhejiang Tailin BioEngineering Co.,Ltd
  5. Zhejiang Tailin Bioengineering Sells $33 Million RMB Convertible Bonds